A multicenter, open-label study to determine the effect of intravenous zoledronic acid (ZOL) on pain and quality of life in patients with bone metastases with or without skeletal-related events (SREs) resulting from breast cancer (BC) and prostate cancer (PC).

被引：0
|
作者：
Al Farhat, Y. B.
Cseh, J.
Boer, K.
Csepreghy, M.
Pajor, L.
Thurzo, L.
Mangel, L.
Esik, O.
机构：
[1] Tolna Cty Balassa Janos Teaching Hosp, Szekszard, Hungary
[2] Fejer Cty St George Hosp, Szekesfehervar, Hungary
[3] Metropolitan Cty St Margaret Hosp, Budapest, Hungary
[4] Metropolitan Cty Bajcsy Zsilinszky Hosp, Budapest, Hungary
[5] Univ Szeged, Teaching Hosp, Fac Med, Szeged City Hosp, Szeged, Hungary
[6] Univ Szeged, Fac Med, Szeged, Hungary
[7] Univ Pecs, Fac Med, Pecs, Hungary
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.e19558
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19558
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Risk of skeletal-related events (SREs) in patients with breast cancer (BC) and newly diagnosed metastases to bone.
    Taneja, Charu
    Lamerato, Lois
    Glass, Andrew
    Richert-Boe, Kathryn E.
    Edelsberg, John
    Wolff, Greg G.
    Czapski, Natalie
    Chung, Karen
    Richhariya, Akshara
    Oster, Gerry
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (27)
  • [2] Risk of skeletal-related events (SREs) in patients with breast cancer (BC) and newly diagnosed metastases to bone.
    Taneja, Charu
    Lamerato, Lois
    Glass, Andrew
    Richert-Boe, Kathryn E.
    Edelsberg, John
    Wolff, Greg G.
    Czapski, Natalie
    Chung, Karen
    Richhariya, Akshara
    Oster, Gerry
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [3] Risk of skeletal-related events (SREs) in patients with prostate cancer (PC) and newly diagnosed metastases to bone.
    Glass, Andrew
    Lamerato, Lois
    Edelsberg, John
    Richert-Boe, Kathryn E.
    Taneja, Charu
    Wolff, Greg G.
    Czapski, Natalie
    Chung, Karen
    Richhariya, Akshara
    Oster, Gerry
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [4] Intravenous and oral ibandronate reduce the risk of skeletal-related events (SREs) in patients with breast cancer and bone metastases
    Tripathy, D.
    Body, J. -J.
    Die, I. J.
    Bergstrom, B.
    EJC SUPPLEMENTS, 2004, 2 (03): : 138 - 138
  • [5] HOSPITAL BURDEN OF DISEASE ASSOCIATED WITH METASTATIC BONE DISEASE (MBD) AND SKELETAL-RELATED EVENTS (SRES) IN PATIENTS WITH BREAST CANCER (BC) AND PROSTATE CANCER (PC) IN SPAIN
    Oglesby, A.
    Pockett, R. D.
    McEwan, P.
    Chung, K.
    VALUE IN HEALTH, 2008, 11 (06) : A477 - A477
  • [6] Breast cancer patients without pain are at risk for skeletal-related events (SRES) and may have better outcomes with zoledronic acid compared with pamidronate
    Costa, Luis
    Chen, Yin-Miao
    Shirina, Nana
    ANNALS OF ONCOLOGY, 2006, 17 : 79 - 79
  • [7] Health care utilization and costs associated with skeletal-related events (SREs) in patients with breast cancer (BC) and bone metastases (BMets).
    Hagiwara, May
    Chung, Karen
    Delea, Thomas E.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (27)
  • [8] RETROSPECTIVE DATABASE ANALYSIS OF THE EFFECT OF ZOLEDRONIC ACID ON SKELETAL-RELATED EVENTS IN MEN WITH PROSTATE CANCER AND BONE METASTASES
    Henk, H. J.
    Kaura, S.
    VALUE IN HEALTH, 2010, 13 (07) : A254 - A254
  • [9] Lung cancer patients without baseline pain are at risk for skeletal-related events (SRES) and have better outcomes with zoledronic acid
    Harper, Peter
    Chen, Yin-Miao
    Shirina, Nana
    ANNALS OF ONCOLOGY, 2006, 17 : 239 - 239
  • [10] A COMPARISON OF DENOSUMAB VERSUS ZOLEDRONIC ACID FOR THE PREVENTION OF SKELETAL-RELATED EVENTS IN BREAST CANCER PATIENTS WITH BONE METASTASES
    Fujiwara, Yasuhiro
    Stopeck, Alison
    de Boer, Richard
    Lichinitser, Mikhail
    Tonkin, Katia
    Yardley, Denise
    Fan, Michelle
    Jiang, Qi
    Jun, Susie
    Dansey, Roger
    Braun, Ada
    ANNALS OF ONCOLOGY, 2010, 21 : 12 - 12
12345